PLUVIA

Pluvia Biotech Announces Publication of Key Patent for PKU lead product PBAS499

Bergen, Norway, 27 February 2025 – Pluvia Biotech (Pluvia), a company dedicated to developing pharmacological chaperones for the treatment of Phenylketonuria (PKU), today announced the publication by the World Intellectual Property Organization (WIPO) of a key Composition of Matter patent application for its lead compound PBAS499.

The patent application was filed in August 2024, which will be the basis to protect the intellectual property of PBAS499 in markets around the world at least up to 2044. The invention relates to compounds for use in the treatment of hyperphenylalaninemia (HPA), in particular phenylketonuria (PKU), acting as pharmacological chaperones of the enzyme phenylalanine hydroxylase. The application contains all relevant data pertaining to PBAS499 including recent data about broad applicability in the majority of high frequency PAH missense variants.

This published patent application recognizes the many years of research by the Pluvia team to develop small molecule pharmacological chaperones with the potential to stabilize the deficient Phenylalanine Hydroxylase (PAH) enzyme, the underlying cause of PKU. The oral lead product PBAS499 shows preclinical efficacy, safety, broad applicability and straightforward manufacturing. Scientific data were presented at the last Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM), Sept 2024.

Mark Scott, Senior Associate and European Patent Attorney at Dehns says: "It is a privilege to support the important work of the Pluvia team by helping them secure the strongest possible intellectual property protection for their invention. The newly published patent application lays the foundation for this protection, and I look forward to working with the team to secure granting of a robust patent in multiple international markets."

Willem van Weperen, Pluvia's CEO adds: "The Pluvia team is proud to execute on another milestone to protect our innovative therapy candidate PBAS499, after having secured Orphan Drug Designations in the US and Europe last year. We are working hard to move this innovation to the clinic to ultimately make a difference for PKU patients."

About PKU

PKU, also known as Følling's disease (named after the Norwegian physician Ivar Asbjørn Følling, the first to identify the disease in 1934), is a rare genetic disorder characterized by the body's inability to break down the amino acid phenylalanine due to a deficiency in the enzyme PAH, caused by genetic variants. This results in the accumulation of phenylalanine in the bloodstream, leading to intellectual disabilities and other neurological problems if left untreated. Patients need a strict lifelong diet without regular protein intake to prevent cognitive impairment. Convenient pharmacological therapy options are needed to help patients to normalize protein intake, while keeping phenylalanine levels within guideline ranges.

About Pluvia Biotech

Pluvia Biotech is a spin-out from the University of Bergen (Norway) dedicated to addressing orphan diseases caused by protein misfolding and having a high unmet medical need. The company's lead program is focused on developing a "first in class" oral pharmacological chaperone treatment of PKU. Through pioneering research and development, Pluvia aims to provide PKU patients with an innovative disease modifying and corrective therapy, and the opportunity to live life without the dietary constraints imposed by the condition. Pluvia's progress is supported by investors Sarsia, Trond Mohn Foundation and Investinor.

For more information about Pluvia Biotech and its innovative work in PKU treatment development, please visit www.pluviabiotech.com. For media inquiries and additional information, please contact info@pluviabiotech.com